FRONTLINE THERAPY OF CHRONIC MYELOID LEUKEMIA (CML)

被引：0
|
作者：
Kantarjian, Hagop [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
LEUKEMIA RESEARCH | 2014年 / 38卷
关键词：
D O I：
10.1016/S0145-2126(14)70007-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
SP-001
引用
收藏
页码：S1 / S1
页数：1
相关论文
共 50 条
  • [31] Outcome After Failure to Second Generation Thyrosine Kinase Inhibitors(TKI) Treatment as Frontline Therapy for Patients with Chronic Myeloid Leukemia (CML) In Chronic Phase(CP)
    Eghtedar, Alireza
    Kantarjian, Hagop
    Jabbour, Elias
    o'Brien, Susan
    Quintas-Cardama, Alfonso
    Burton, Elizabeth
    Garcia-Manero, Guillermo
    Verstovsek, Srdan
    Konopleva, Marina
    Cortes, Jorge E.
    BLOOD, 2010, 116 (21) : 1411 - 1412
  • [32] Frontline therapy in Chronic Lymphocytic Leukemia
    Arguello-Tomas, Miguel
    Albiol, Nil
    Moreno, Carol
    ACTA HAEMATOLOGICA, 2024, 147 (01) : 49 - 61
  • [33] Update on lower-dose dasatinib 50 mg daily as frontline therapy in newly diagnosed chronic phase chronic myeloid leukemia (CML-CP).
    Naqvi, Kiran
    Jabbour, Elias
    Skinner, Jeffrey A.
    Anderson, Kristin N.
    Yilmaz, Musa
    Jain, Nitin
    Ferrajoli, Alessandra
    Bose, Prithviraj
    Thompson, Philip A.
    Alvarado, Yesid
    Takahashi, Koichi
    Burger, Jan Andreas
    Borthakur, Gautam
    Estrov, Zeev
    Pemmaraju, Naveen
    Paul, Shilpa
    Dellasala, Sara
    Cortes, Jorge E.
    Kantarjian, Hagop M.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [34] Ponatinib As Initial Therapy For Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP)
    Cortes, Jorge E.
    Borthakur, Gautam
    Pemmaraju, Naveen
    Daver, Naval
    Quintas-Cardama, Alfonso
    Ravandi, Farhad
    Gachimova, Evguenia
    Estrov, Zeev
    Jabbour, Elias
    O'Brien, Susan
    Kantarjian, Hagop
    BLOOD, 2013, 122 (21)
  • [35] Dasatinib as initial therapy for patients with chronic myeloid leukemia (CML) in early chronic phase (CP)
    Pemmaraju, Naveen
    Kantarjian, Hagop
    O'Brien, Susan
    Luthra, Raja
    Jabbour, Elias
    Quintas-Cardama, Aflonso
    Borthakur, Gautam
    Ravandi, Farhad
    Burton, Elizabeth
    Walker, Brenda
    Cortes, Jorge
    CANCER RESEARCH, 2011, 71
  • [36] Sequential Treatments in Chronic Phase Chronic Myeloid Leukemia (CML) Patients without Optimal Response after Frontline Nilotinib or Dasatinib: An Italian CML Campus Study
    Gugliotta, Gabriele
    Annunziata, Mario
    Capodanno, Isabella
    Rapezzi, Davide
    Attolico, Immacolata
    Vincelli, Iolanda Donatella
    Tiribelli, Mario
    Malato, Alessandra
    Pizzuti, Michele
    Accurso, Vincenzo
    Bonifacio, Massimiliano
    Galimberti, Sara
    Loglisci, Giuseppina
    Abruzzese, Elisabetta
    Bocchia, Monica
    Gozzini, Antonella
    Bergamaschi, Micaela
    Miggiano, Maria Cristina
    Tafuri, Agostino
    Sanpaolo, Grazia
    Binotto, Gianni
    Castagnetti, Fausto
    Specchia, Giorgina
    Di Raimondo, Francesco
    Cavo, Michele
    Rosti, Gianantonio
    Foa, Robin
    Saglio, Giuseppe
    Breccia, Massimo
    Stagno, Fabio
    BLOOD, 2020, 136
  • [37] Selecting the Best Frontline Treatment in Chronic Myeloid Leukemia
    Yilmaz, Musa
    Abaza, Yasmin
    Jabbour, Elias
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2015, 10 (02) : 145 - 157
  • [38] Selecting the Best Frontline Treatment in Chronic Myeloid Leukemia
    Musa Yilmaz
    Yasmin Abaza
    Elias Jabbour
    Current Hematologic Malignancy Reports, 2015, 10 : 145 - 157
  • [39] Can We and Should We Improve on Frontline Imatinib Therapy for Chronic Myeloid Leukemia?
    Fava, Carmen
    Saglio, Giuseppe
    SEMINARS IN HEMATOLOGY, 2010, 47 (04) : 319 - 326
  • [40] THERAPY OF CHRONIC MYELOID-LEUKEMIA (CML) - INTERIM-REPORT ON PROTOCOLS CML-73 AND CML-74
    BACCARANI, M
    RUGGERO, D
    TURA, S
    BOLLETTINO DELL ISTITUTO SIEROTERAPICO MILANESE, 1978, 57 (03): : 278 - 288
12345